Cartesian Therapeutics CTO Metin Kurtoglu to depart May 1; will serve as consultant through April 2026

Cartesian Therapeutics, Inc.

CTO Metin Kurtoglu's employment ends May 1, 2025; consulting agreement runs through April 30, 2026.
Separation agreement includes 12 months salary, pro-rated bonus eligibility, and accelerated vesting of equity awards granted Jan 2, 2024.
Release of claims upon receipt of severance benefits as per employment agreement dated March 28, 2024.
No replacement named; Dr. Kurtoglu will remain in advisory role under consulting terms.

item 5.02

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001453687-25-000077
form_type: 8-K
ticker: RNAC
cik: 0001453687
company_name: Cartesian Therapeutics, Inc.
filed_at: 2025-04-29T23:59:59+00:00
discovered_at: 2026-05-14T18:02:48.332545+00:00
generated_at: 2026-05-23T03:41:09.805910+00:00
sec_items: ["5.02"]
event_type: leadership
sentiment: neutral
materiality_score: 0.5
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001453687-25-000077
json_url: https://secwatch.observer/filing/0001453687-25-000077.json
markdown_url: https://secwatch.observer/filing/0001453687-25-000077.md
text_url: https://secwatch.observer/filing/0001453687-25-000077.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000077/0001453687-25-000077-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000077/rnac-20250429.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Metin Kurtoglu

Chief Technology Officer

RNAC · Cartesian Therapeutics, Inc.

Effective: 2025-05-01
Filed: Apr 29, 2025 23:59 UTC

Dr. Kurtoglu’s employment with the Company will end effective May 1, 2025

Source-grounded claims

43b4aa7367

Metin Kurtoglu departed as Chief Technology Officer at Cartesian Therapeutics, Inc..

Dr. Kurtoglu’s employment with the Company will end effective May 1, 2025

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

Source: SEC EDGAR

accession 0001453687-25-000077

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.